Skip to main content
Top
Published in: Osteoporosis International 5/2019

01-05-2019 | Magnetic Resonance Imaging | Case Report

Bisphosphonate-induced orbital inflammation: more common than once thought?

Authors: L.K. Chehade, D. Curragh, D. Selva

Published in: Osteoporosis International | Issue 5/2019

Login to get access

Abstract

To report two cases of bisphosphonate-induced orbital inflammation, discuss the clinic-radiological features and management options, and highlight the increasing frequency of an association previously considered extremely rare. A retrospective review of two cases presenting to our department, and review of the literature reporting this association. Two new cases of bisphosphonate-induced orbital inflammation were added to the literature. The first occurred in the context of a risedronate re-challenge, and the second with zoledronic acid. Both cases were managed successfully with topical steroids. Clinicians prescribing bisphosphonates, particularly for the first time, should be aware of the increasingly reported association with orbital inflammation. The presence of suggestive clinical features should prompt urgent referral to an ophthalmologist for appropriate management.
Literature
1.
go back to reference NICE (2017) TA464: bisphosphonates for treating osteoporosis. National Institute for Health and Care Excellence, London NICE (2017) TA464: bisphosphonates for treating osteoporosis. National Institute for Health and Care Excellence, London
2.
go back to reference Mbekeani JN, Slamovits TL, Schwartz BH, Sauer HL (1999) Ocular inflammation associated with alendronate therapy. Arch Ophthalmol 117(6):837–838PubMed Mbekeani JN, Slamovits TL, Schwartz BH, Sauer HL (1999) Ocular inflammation associated with alendronate therapy. Arch Ophthalmol 117(6):837–838PubMed
3.
go back to reference Umunakwe OC, Herren D, Kim SJ, Kohanim S (2017) Diffuse ocular and orbital inflammation after zoledronate infusion-case report and review of the literature. Digit J Ophthalmol 23(4):18–21CrossRefPubMed Umunakwe OC, Herren D, Kim SJ, Kohanim S (2017) Diffuse ocular and orbital inflammation after zoledronate infusion-case report and review of the literature. Digit J Ophthalmol 23(4):18–21CrossRefPubMed
4.
go back to reference Lefebvre DR, Mandeville JT, Yonekawa Y, Arroyo JG, Torun N, Case Series FSKA (2016) Review of bisphosphonate-associated orbital inflammation. Ocul Immunol Inflamm 24(2):134–139PubMed Lefebvre DR, Mandeville JT, Yonekawa Y, Arroyo JG, Torun N, Case Series FSKA (2016) Review of bisphosphonate-associated orbital inflammation. Ocul Immunol Inflamm 24(2):134–139PubMed
5.
go back to reference Pirbhai A, Rajak SN, Goold LA, Cunneen TS, Wilcsek G, Martin P et al (2015) Bisphosphonate-induced orbital inflammation: a case series and review. Orbit (Amsterdam, Netherlands) 34(6):331–335 Pirbhai A, Rajak SN, Goold LA, Cunneen TS, Wilcsek G, Martin P et al (2015) Bisphosphonate-induced orbital inflammation: a case series and review. Orbit (Amsterdam, Netherlands) 34(6):331–335
6.
go back to reference Ryan PJ, Sampath R (2001) Idiopathic orbital inflammation following intravenous pamidronate. Rheumatology (Oxford, England) 40(8):956–957CrossRef Ryan PJ, Sampath R (2001) Idiopathic orbital inflammation following intravenous pamidronate. Rheumatology (Oxford, England) 40(8):956–957CrossRef
7.
go back to reference Subramanian PS, Kerrison JB, Calvert PC, Miller NR (2003) Orbital inflammatory disease after pamidronate treatment for metastatic prostate cancer. Arch Ophthalmol 121(9):1335–1336CrossRefPubMed Subramanian PS, Kerrison JB, Calvert PC, Miller NR (2003) Orbital inflammatory disease after pamidronate treatment for metastatic prostate cancer. Arch Ophthalmol 121(9):1335–1336CrossRefPubMed
8.
go back to reference Phillips PM, Newman SA (2008) Orbital inflammatory disease after intravenous infusion of zoledronate for treatment of metastatic renal cell carcinoma. Arch Ophthalmol (Chicago, Ill : 1960) 126(1):137–139CrossRef Phillips PM, Newman SA (2008) Orbital inflammatory disease after intravenous infusion of zoledronate for treatment of metastatic renal cell carcinoma. Arch Ophthalmol (Chicago, Ill : 1960) 126(1):137–139CrossRef
9.
go back to reference Sharma NS, Ooi JL, Masselos K, Hooper MJ, Francis IC (2008) Zoledronic acid infusion and orbital inflammatory disease. N Engl J Med 359(13):1410–1411CrossRefPubMed Sharma NS, Ooi JL, Masselos K, Hooper MJ, Francis IC (2008) Zoledronic acid infusion and orbital inflammatory disease. N Engl J Med 359(13):1410–1411CrossRefPubMed
10.
go back to reference Seth A, Anderson DP, Albiani DA, Barton JJ (2009) Orbital inflammation and optic neuropathy with zoledronic acid for metastatic prostate cancer. Can J Ophthalmol 44(4):467–468CrossRefPubMed Seth A, Anderson DP, Albiani DA, Barton JJ (2009) Orbital inflammation and optic neuropathy with zoledronic acid for metastatic prostate cancer. Can J Ophthalmol 44(4):467–468CrossRefPubMed
11.
go back to reference Missotten G, Verheezen Y (2010) Orbital inflammation after use of zoledronic acid for metastasized prostate carcinoma. Bull Soc Belge Ophtalmol 315:23–24 Missotten G, Verheezen Y (2010) Orbital inflammation after use of zoledronic acid for metastasized prostate carcinoma. Bull Soc Belge Ophtalmol 315:23–24
12.
go back to reference Procianoy F, Procianoy E (2010) Orbital inflammatory disease secondary to a single-dose administration of zoledronic acid for treatment of postmenopausal osteoporosis. Osteoporos Int 21(6):1057–1058CrossRefPubMed Procianoy F, Procianoy E (2010) Orbital inflammatory disease secondary to a single-dose administration of zoledronic acid for treatment of postmenopausal osteoporosis. Osteoporos Int 21(6):1057–1058CrossRefPubMed
13.
go back to reference Yang EB, Birkholz ES, Lee AG (2010) Another case of bisphosphonate-induced orbital inflammation. J Neuroophthalmol 30(1):94–95CrossRefPubMed Yang EB, Birkholz ES, Lee AG (2010) Another case of bisphosphonate-induced orbital inflammation. J Neuroophthalmol 30(1):94–95CrossRefPubMed
14.
go back to reference Yeo J, Jafer AK (2010) Zolendronate associated inflammatory orbital disease. N Z Med J 123(1323):50–52PubMed Yeo J, Jafer AK (2010) Zolendronate associated inflammatory orbital disease. N Z Med J 123(1323):50–52PubMed
15.
go back to reference Kaur H, Uy C, Kelly J, Moses AM (2011) Orbital inflammatory disease in a patient treated with zoledronate. Endocr Pract 17(4):e101–e103CrossRefPubMed Kaur H, Uy C, Kelly J, Moses AM (2011) Orbital inflammatory disease in a patient treated with zoledronate. Endocr Pract 17(4):e101–e103CrossRefPubMed
16.
go back to reference Ortiz-Perez S, Fernandez E, Molina JJ, Sanchez-Dalmau B, Navarro M, Corretger X et al (2011) Two cases of drug-induced orbital inflammatory disease. Orbit (Amsterdam, Netherlands) 30(1):37–39 Ortiz-Perez S, Fernandez E, Molina JJ, Sanchez-Dalmau B, Navarro M, Corretger X et al (2011) Two cases of drug-induced orbital inflammatory disease. Orbit (Amsterdam, Netherlands) 30(1):37–39
17.
go back to reference Schwab P, Harmon D, Bruno R, Fraunfelder FW, Hyunchung Kim D (2012) A 55-year-old woman with orbital inflammation. Arthritis Care Res 64(11):1776–1782CrossRef Schwab P, Harmon D, Bruno R, Fraunfelder FW, Hyunchung Kim D (2012) A 55-year-old woman with orbital inflammation. Arthritis Care Res 64(11):1776–1782CrossRef
18.
go back to reference Boni C, Kordic H, Chaloupka K (2013) Bisphosphonate-associated orbital inflammatory disease and uveitis anterior--a case report and review. Klin Monbl Augenheilkd 230(4):367–369CrossRefPubMed Boni C, Kordic H, Chaloupka K (2013) Bisphosphonate-associated orbital inflammatory disease and uveitis anterior--a case report and review. Klin Monbl Augenheilkd 230(4):367–369CrossRefPubMed
19.
go back to reference Peterson JD, Bedrossian EH Jr (2012) Bisphosphonate-associated orbital inflammation--a case report and review. Orbit (Amsterdam, Netherlands) 31(2):119–123 Peterson JD, Bedrossian EH Jr (2012) Bisphosphonate-associated orbital inflammation--a case report and review. Orbit (Amsterdam, Netherlands) 31(2):119–123
20.
go back to reference Vora MM, Rodgers IR, Uretsky S (2014) Nitrogen bisphosphonate-induced orbital inflammatory disease: gamma delta T cells--a report and review of 2 cases. Ophthalmic Plast Reconstr Surg 30(4):e84–e85CrossRefPubMed Vora MM, Rodgers IR, Uretsky S (2014) Nitrogen bisphosphonate-induced orbital inflammatory disease: gamma delta T cells--a report and review of 2 cases. Ophthalmic Plast Reconstr Surg 30(4):e84–e85CrossRefPubMed
21.
go back to reference Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M (2000) Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96(2):384–392PubMed Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M (2000) Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96(2):384–392PubMed
22.
go back to reference Mbekeani JN, Slamovits TL, Schwartz BH, Sauer HL (1999) Ocular inflammation associated with alendronate therapy. Arch Ophthalmol 117(6):837–838PubMed Mbekeani JN, Slamovits TL, Schwartz BH, Sauer HL (1999) Ocular inflammation associated with alendronate therapy. Arch Ophthalmol 117(6):837–838PubMed
Metadata
Title
Bisphosphonate-induced orbital inflammation: more common than once thought?
Authors
L.K. Chehade
D. Curragh
D. Selva
Publication date
01-05-2019
Publisher
Springer London
Published in
Osteoporosis International / Issue 5/2019
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-019-04850-w

Other articles of this Issue 5/2019

Osteoporosis International 5/2019 Go to the issue